DE602004012725D1 - Quinazolin-derivate für die behandling von krebs - Google Patents

Quinazolin-derivate für die behandling von krebs

Info

Publication number
DE602004012725D1
DE602004012725D1 DE602004012725T DE602004012725T DE602004012725D1 DE 602004012725 D1 DE602004012725 D1 DE 602004012725D1 DE 602004012725 T DE602004012725 T DE 602004012725T DE 602004012725 T DE602004012725 T DE 602004012725T DE 602004012725 D1 DE602004012725 D1 DE 602004012725D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
quinazoline derivatives
quinazoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004012725T
Other languages
English (en)
Other versions
DE602004012725T2 (de
Inventor
Nicola Murdoch Heron
Georges Rene Pasquet
Andrew Austen Mortlock
Frederic Henri Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004012725D1 publication Critical patent/DE602004012725D1/de
Application granted granted Critical
Publication of DE602004012725T2 publication Critical patent/DE602004012725T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602004012725T 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs Expired - Lifetime DE602004012725T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16
EP03290951 2003-04-16
PCT/GB2004/001614 WO2004094410A1 (en) 2003-04-16 2004-04-14 Chemical compounds

Publications (2)

Publication Number Publication Date
DE602004012725D1 true DE602004012725D1 (de) 2008-05-08
DE602004012725T2 DE602004012725T2 (de) 2009-04-16

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012725T Expired - Lifetime DE602004012725T2 (de) 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs

Country Status (23)

Country Link
US (1) US7691867B2 (de)
EP (1) EP1613619B1 (de)
JP (1) JP4709139B2 (de)
KR (1) KR20060003351A (de)
CN (1) CN1809557B (de)
AR (1) AR043875A1 (de)
AT (1) ATE390422T1 (de)
AU (1) AU2004232527A1 (de)
BR (1) BRPI0409427A (de)
CA (1) CA2522079A1 (de)
CL (1) CL2004000797A1 (de)
CO (1) CO5640037A2 (de)
DE (1) DE602004012725T2 (de)
ES (1) ES2301981T3 (de)
HK (1) HK1086573A1 (de)
IS (1) IS8125A (de)
MX (1) MXPA05011076A (de)
NO (1) NO20054842L (de)
RU (1) RU2005135337A (de)
TW (1) TW200510392A (de)
UY (1) UY28271A1 (de)
WO (1) WO2004094410A1 (de)
ZA (1) ZA200508372B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1463506T1 (sl) * 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
GEP20084551B (en) 2004-05-06 2008-11-25 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
KR20070084172A (ko) 2004-10-12 2007-08-24 아스트라제네카 아베 퀴나졸린 유도체
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
DE602005026557D1 (de) 2004-11-17 2011-04-07 Korea Res Inst Chem Tech 1-ä(6-substituiertes alkoxychinoxalinyl) aminocarbonylü-4-(hetero)arylpiperazinderivate
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
EP1888572A1 (de) * 2005-05-28 2008-02-20 AstraZeneca AB Chinazoline und ihre verwendung als aurorakinaseinhibitoren
US20080269500A1 (en) * 2005-09-22 2008-10-30 Astrazeneca Ab Process for the Preparation of 4-Aminopyrazole Derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1994023A1 (de) * 2006-03-02 2008-11-26 AstraZeneca AB Chinazolinderivate
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
RU2016112013A (ru) * 2013-09-19 2017-10-24 Пьер Фабр Медикамент Производные хиназолина и их применение в качестве ингибиторов днк-метилтрансферазы

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HUP0301236A2 (hu) * 2000-06-28 2003-10-28 Astrazeneca Ab, Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
SI1463506T1 (sl) 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
JPWO2004018430A1 (ja) * 2002-08-23 2005-12-08 麒麟麦酒株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
ATE412657T1 (de) 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
KR20050087863A (ko) * 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ATE390422T1 (de) 2008-04-15
CL2004000797A1 (es) 2005-05-27
JP4709139B2 (ja) 2011-06-22
US7691867B2 (en) 2010-04-06
CN1809557A (zh) 2006-07-26
MXPA05011076A (es) 2006-01-24
RU2005135337A (ru) 2006-06-10
EP1613619B1 (de) 2008-03-26
AR043875A1 (es) 2005-08-17
UY28271A1 (es) 2004-11-30
HK1086573A1 (en) 2006-09-22
CN1809557B (zh) 2012-07-04
US20060270692A1 (en) 2006-11-30
ZA200508372B (en) 2007-04-25
AU2004232527A1 (en) 2004-11-04
TW200510392A (en) 2005-03-16
IS8125A (is) 2005-11-11
BRPI0409427A (pt) 2006-04-18
JP2006523660A (ja) 2006-10-19
ES2301981T3 (es) 2008-07-01
KR20060003351A (ko) 2006-01-10
DE602004012725T2 (de) 2009-04-16
EP1613619A1 (de) 2006-01-11
WO2004094410A1 (en) 2004-11-04
CA2522079A1 (en) 2004-11-04
NO20054842L (no) 2005-11-08
CO5640037A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
NL1029763A1 (nl) Bereiding van gesubstitueerde chinazolinen.
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602004004553D1 (de) Chinazolinderivate
DE602004022180D1 (de) Chinazolinderivate
IS7362A (is) Kínasólín efnasambönd
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20054967D0 (no) Ammoniakk oksidasjonsprosess
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE372674T1 (de) N-arylhydrazonderivate für die saatgutbehandlung
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1678085T3 (da) Fluidbehandlingsindretning
NO20063114L (no) Enoxaparin for behandling av cancer
ATE366242T1 (de) 5-substituierte chinazolinonderivate
NO20055449D0 (no) Fremgangsmate for diagnostisering av behandling av kreft
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
ITVR20030088A1 (it) Procedimento per la realizzazione di fasce anti-implosione per cinescopi
NO20042850L (no) Kreftbehandling
ATA11142004A (de) Phosphatierverfahren und bauteil
ATE520402T1 (de) Anti-egfr-antikörper und vegfr-inhibitoren umfassende kombinationen für die behandlung von krebs
DK1824975T3 (da) LNA Oligonukleotider og behandlingen af cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition